We’re excited to present new preclinical data on ORKA-001, a novel extended half-life monoclonal antibody targeting IL-23p19, at the EADV Congress in Amsterdam. The data show that ORKA-001 has a three-fold longer half-life in non-human primates than risankizumab, while binding to a similar epitope with similar affinity. These findings give us additional confidence that ORKA-001 can achieve our base-case expectation of dosing once every six months and further reason to believe we could reach once-yearly dosing with the potential for higher efficacy, all with the goal of offering people with psoriasis the most possible freedom from their disease.
关于我们
Advancing novel biologics that aim to offer the greatest possible freedom from disease to people with plaque psoriasis and other associated conditions
- 网站
-
www.orukatx.com
Oruka Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 类型
- 上市公司
Oruka Therapeutics员工
动态
-
We’re excited to begin trading on Nasdaq as “ORKA” today following the close of our merger. This transaction and concurrent $275 million financing propel us towards our goal of offering the greatest possible freedom from disease to patients with psoriasis and other associated diseases.
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million | Tue, 09/03/2024 - 07:00
ir.orukatx.com